Expert Interview
A Third Look: Discussing the Topline Data from TEPEZZA (teprotutumab) in phase 4 Clinical Trial in Patients with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
Ticker(s): HZNPInstitution: Cedars Sinai
- Professor and Head of Orbital and Thyroid Eye Disease Programs at Cedars Sinai Hospital.
- Pioneered the Aesthetic Orbital Decompression technique, which addresses both eye aesthetic and function.
- Internationally recognized as a key player in the development and use of TEPEZZA (Teprotumumab).
- Research focuses on aesthetic and reconstructive oculoplastic surgery as well as thyroid eye disease treatment and transformations.
How many patients with CAS-TED do you treat?
Added By: wilson_adminWhat is your impression of the phase 4 data?
Will you use Tepezza in CAS-TED patients?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
